Osteoclasts are bone-resorbing cells that are derived from haemopoietic precursors, including cells present in peripheral blood. The recent identification of RANKL [receptor activator of nuclear factor (NF)-κB ligand], a new member of the tumour necrosis factor ligand superfamily that has a key role in osteoclastogenesis, has allowed the in vitro generation of osteoclasts in the absence of cells of the stromal/osteoblast lineage. Human peripheral blood mononuclear cells (PBMC) cultured in vitro with soluble RANKL and human macrophage colony-stimulating factor form osteoclasts. However, PBMC are heterogeneous, consisting of subsets of monocytes and lymphocytes as well as other blood cells. As the CD14 marker is strongly expressed on monocytes, the putative osteoclast precursor in peripheral blood, we have selected CD14 + cells from PBMC to examine their osteoclastogenic potential and their expression of novel members of the tumour necrosis factor superfamily involved in osteoclastogenesis. Highly purified CD14 + cells demonstrated mRNA expression of receptor activator of NF-κB, but no expression of RANKL or osteoprotegerin, whereas PBMC expressed mRNAs for all three factors. CD14 + (but not CD14 − ) cells cultured on bone slices for 21 days with human macrophage colony-stimulating factor and soluble RANKL generated osteoclasts and showed extensive bone resorption. Similar numbers of osteoclasts were generated by 10 5 CD14 + cells and 10 6 PBMC, but there was significantly less intra-assay variability with CD14 + cells, suggesting the absence of stimulatory/ inhibitory factors from these cultures. The ability of highly purified CD14 + cells to generate osteoclasts will facilitate further characterization of the phenotype of circulating osteoclast precursors and cell interactions in osteoclastogenesis.
Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor κB ligand (RANKL)
A B S T R A C T
Osteoclasts are bone-resorbing cells that are derived from haemopoietic precursors, including cells present in peripheral blood. The recent identification of RANKL [receptor activator of nuclear factor (NF)-κB ligand], a new member of the tumour necrosis factor ligand superfamily that has a key role in osteoclastogenesis, has allowed the in vitro generation of osteoclasts in the absence of cells of the stromal/osteoblast lineage. Human peripheral blood mononuclear cells (PBMC) cultured in vitro with soluble RANKL and human macrophage colony-stimulating factor form osteoclasts. However, PBMC are heterogeneous, consisting of subsets of monocytes and lymphocytes as well as other blood cells. As the CD14 marker is strongly expressed on monocytes, the putative osteoclast precursor in peripheral blood, we have selected CD14 + cells from PBMC to examine their osteoclastogenic potential and their expression of novel members of the tumour necrosis factor superfamily involved in osteoclastogenesis. Highly purified CD14 + cells demonstrated mRNA expression of receptor activator of NF-κB, but no expression of RANKL or osteoprotegerin, whereas PBMC expressed mRNAs for all three factors. CD14 + (but not CD14 − ) cells cultured on bone slices for 21 days with human macrophage colony-stimulating factor and soluble RANKL generated osteoclasts and showed extensive bone resorption. Similar numbers of osteoclasts were generated by 10 5 CD14 + cells and 10 6 PBMC, but there was significantly less intra-assay variability with CD14 + cells, suggesting the absence of stimulatory/ inhibitory factors from these cultures. The ability of highly purified CD14 + cells to generate osteoclasts will facilitate further characterization of the phenotype of circulating osteoclast precursors and cell interactions in osteoclastogenesis.
INTRODUCTION
The bone-resorbing cell, the osteoclast, is derived from macrophage colony-stimulating factor (M-CSF)-dependent haemopoietic precursors, including mononuclear cells present in the peripheral circulation [1] [2] [3] . In vitro generation of osteoclasts in co-cultures of adherent peripheral blood mononuclear cells (PBMC) and stromal\osteoblastic cells has been demonstrated in both murine [4, 5] and human [6] [7] [8] [9] systems. Recently, the requirement for co-culture with stromal\osteoblastic cells has been circumvented by the identification of a factor expressed on the membrane of stromal\osteoblast cells that mediates osteoclast differentiation (reviewed in [10] ). This factor, a novel type II membrane protein of the tumour necrosis factor (TNF) ligand superfamily, was initially identified in dendritic cells as TNF-related activation-induced cytokine (' TRANCE ') [11] . Subsequently, identical proteins were independently identified as receptor activator of nuclear factor (NF)-κB ligand (RANKL) [12] , osteoclast differentiation factor [13] and osteoprotegerin (OPG) ligand [14] . As suggested [10] , this factor will be referred to as RANKL in this paper. RANKL acts on osteoclast precursors via a membrane receptor, RANK (receptor activator of NF-κB) [15, 16] , but can also bind to a second receptor, OPG, a secreted glycoprotein [13, 14, 17] . OPG can thus function as a ' decoy ' receptor for RANKL, in this way inhibiting osteoclastogenesis, a function which led to its identification as ' osteoclastogenesis inhibitory factor ' [18] .
Matsuzaki et al. [19] incubated washed adherent human PBMC with human M-CSF (hM-CSF) and soluble mouse RANKL (sRANKL ; comprising the extracellular domain of mouse RANKL) and generated large numbers of tartrate-resistant acid phosphatase-positive (TRAP + ), vitronectin-receptor-positive multinucleate cells that resorbed dentine slices extensively. However, when the non-adherent cells (which are mostly lymphocytes) were not removed, dexamethasone was required for osteoclastogenesis to occur, suggesting the presence of a dexamethasone-suppressible inhibitory factor(s) in this population. Quinn et al. [20] generated bone-resorbing osteoclasts from mouse and human PBMC and mouse spleen cells treated with sRANKL and hM-CSF. In that study, 95 % of the human cells adherent to glass coverslips expressed the macrophage-associated antigens CD68, CD11b and CD14, suggesting that osteoclasts are derived from CD14-positive (CD14 + ) monocytes. However, phenotypic expression was not examined on cells adherent to bone slices. Nevertheless, the recent results of Massey and Flanagan [21] , who found that selection of CD14 + cells from PBMC enhanced osteoclastic bone resorption in co-cultures with UMR 106 rat osteoblastlike cells, provide further evidence that the osteoclast precursor is CD14 + .
The above results indicate that there is an osteoclast precursor within the PBMC population and, although PBMC are a heterogeneous population (monocytes, lymphocytes and smaller numbers of other blood cell types), the most likely candidate for the osteoclast precursor in this population is the CD14 + monocyte. The aim of the present study was to determine whether ' monocultures ' of highly purified CD14 + cells selected from PBMC could generate osteoclasts when cultured on bone with sRANKL and hM-CSF, and also to examine the expression of RANK, RANKL and OPG mRNAs in CD14 + cells. Preparation of total PBMC, CD14 + PBMC and CD14-negative (CD14 − ) PBMC Buffy coats obtained from the blood of healthy donors were provided anonymously by the Red Cross Blood Bank, under a protocol approved by Barwon Health Human Research and Ethics Advisory Committee. To isolate PBMC, the buffy coats were diluted 1 : 1 (v\v) in PBS, layered over Ficoll-Paque solution and centrifuged (400 g for 30 min). The PBMC layer was collected and washed in 5-6 vol. of PBS, isolated by centrifugation (140 g) and resuspended in minimum essential medium containing 10 % (v\v) fetal bovine serum. Prior to CD14 + enrichment, granulocyte contamination of PBMC was reduced to 1 % by performing two Ficoll-Paque separations. A portion of 20 µl of MACS Microbeads, conjugated with a monoclonal mouse anti-(human CD14) antibody, was added to 10( PBMC in 80 µl of PBS and incubated for 15 min at 4 mC. Cells were then washed with 10-20i buffer volume and centrifuged at 300 g for 10 min. The supernatant was aspirated and the cells were resuspended in buffer at a concentration of 10) cells\ 500 µl. The cell suspension was added to a VS + positive selection column mounted on a magnetic separator. The RANKL induces osteoclasts from CD14 + human mononuclear cells CD14 − cell population was rinsed through the column with 3i3 ml of PBS and collected for parallel culture.
MATERIALS AND METHODS

Materials
The column was removed from the magnetic separator and the CD14 + cell fraction flushed through. Samples of 10& cells from the PBMC, CD14 + and CD14 − fractions were treated with anti-CD14 conjugated to fluorescein isothiocyanate and anti-CD45 conjugated to phycoerythrin, and analysed by fluorescence-activated cytometry using a FACSCalibur (Becton Dickinson).
Gene expression by comparative reverse transcription (RT)-PCR
PBMC (2i10() or CD14 + cells (2i10') were settled on to 25 cm# culture flasks and incubated at 37 mC in 5% CO # with hM-CSF (25 ng\ml). After 24 h the cells were lysed in RNAzol B solution and total RNA was extracted according to the manufacturer's instructions. For RT and PCR reactions, a Perkin Elmer\Cetus DNA Thermal Cycler was used. RT was performed in the presence of 5 mM MgCl # , 1 mM deoxynucleotide mixture, 3.2 µg of random primers, 50 units of RNase inhibitor and 20 units of AMV (avian myeloblastosis virus) reverse transcriptase. The final mixture was allowed to react at 25 mC for 10 min, 42 mC for 60 min and 95 mC for 5 min to denature the enzyme. Sense and antisense primers were designed using the MacVector program and synthesized by Gibco BRL (Gaithersburg, MD, U.S.A.). Sequences and sizes are shown in Table 1 . PCR products were confirmed either by restriction enzyme digestion or by sequencing, and primer pairs spanned intron-exon splice sites, allowing for the detection of mRNA only. PCR amplification was performed with cycles of denaturation at 95 mC for 1 min, annealing at 55 mC for 2 min and extension at 72 mC for 1 min. The reaction mixture contained 40 pmol of each primer, 200 mM dNTPs, 2 µl of 10i reaction buffer, optimized concentration of MgCl # (1.0 mM), 1 unit of Taq DNA polymerase and sterile distilled water to a volume of 20 µl. The mixture was then overlaid with paraffin oil. For comparative RT-PCR analysis, the optimal number of cycles for each gene was determined as follows : glyceraldehyde-3-phosphate dehydrogenase, 20 cycles ; RANK and RANKL, 34 cycles ; OPG, 38 cycles. PCR products were resolved on a 1.2 % (w\v) agarose gel and visualized using ethidium bromide. The size of the bands was confirmed by comparison with a 100 bp DNA ladder (Gibco BRL). cDNA from a sample of human giant cell tumour of bone was used as a positive control, as it was found to express all the genes studied.
Osteoclast generation
PBMC (10'\well), CD14 + cells (10&\well) or CD14 − cells (10&\well) were added to 6 mm-diameter culture wells containing slices of sterilized bovine cortical bone of dimensions 4 mmi4 mmi0.5 mm (six slices\treat-ment). For the PBMC cultures, the wells were aspirated at 2 h to remove non-adherent cells and fresh medium was added. The cultures were maintained in 200 µl of minimum essential medium containing 10 % (v\v) fetal bovine serum and 100 units\ml benzyl penicillin for 21 days in the presence of hM-CSF (25 ng\ml) and the presence or absence of sRANKL (40 ng\ml). All media and added factors were replaced twice weekly. In the time-course assay, cell counts at 24 h (when TRAP reactions were not evident) were obtained by staining with Methylene Blue. At later time points TRAP staining allowed the quantification of TRAP + mononuclear cells (Mo) and TRAP + multinuclear ( 2 nuclei) cells (MNC). At various times, the cells were then removed from the bone slices by ultrasonication and the slices were processed for scanning electron microscopy. The percentage of bone surface resorbed was quantified at 100-150i magnification.
Cytochemistry of non-specific esterase (NSE)
Following 18 h of culture, the bone slices were rinsed to remove non-adherent cells and the adherent cells were fixed in ice-cold acetone for 10 min, then air-dried. The fixed cells were tested for α-naphthyl acetate esterase (NSE) in the absence and presence of 18 mM NaF according to the manufacturer's instructions (Sigma).
CD marker immunocytochemistry
Bone slices containing PBMC or CD14 + cells were removed from culture at various times for analysis of CD marker expression on adherent cells. They were placed in 100 µl of culture medium at 4 mC for immunostaining with fluorescent conjugates of monoclonal antibodies against CD markers. The cells were fixed in ice-cold acetone or 4 % paraformaldehyde and then stained with TOTO-3 (Molecular Probes) in the presence of RNase. Monoclonal antibodies against combinations CD14\ CD13 and CD19\CD3 were used to determine the proportion of cells on the slices expressing the different markers. To determine the proportion of CD14 + cells to the total leucocyte number, the antibody combination CD14\CD45 was used. Fluorescently labelled IgG2a and IgG1 isotype immunoglobulins were used as controls for non-specific binding. Analyses were performed on an inverted Leica DMR-1B microscope with a Bio-Rad 1024 confocal laser scanning microscope.
RESULTS
Fluorescence-activated cytometric analysis
Fluorescence-activated cytometric analysis of the PBMC samples showed that 13.8p2.8 % (meanpS.E.M. ; n l 6) of the cells were CD14 + . Following CD14 enrichment using the MACS system, 89p4% (n l 4) were CD14 + , whereas 0.03 % of the CD14 − fraction were CD14 + (results not shown). 
Gene expression
In PBMC, expression of RANK, RANKL and OPG mRNAs was evident when assessed by RT-PCR. However, in purified CD14 + cells only expression of RANK (Figure 1 ). The faint bands seen in lanes B and C of Figure 1 are larger than the OPG mRNA, and when sequenced were non-specific. In addition, no OPG mRNA was detected in CD14 + preparations using TaqMan (real time) PCR (results not shown).
Characterization of the bone-adherent population
TRAP and NSE enzyme cytochemistry
In cultures of PBMC, CD14 + and CD14 − , the cells adherent to the bone slices at 18 h were uniformly mononuclear and negative for TRAP. In the CD14 + cultures at least 95 % of the cells showed moderate to strong reactions for fluoride-sensitive NSE, a characteristic of monocytes (results not shown). In the PBMC cultures the proportion of fluoride-sensitive NSE + cells was variable (40-80 %) in different regions of the bone slices. The CD14 − cultures were not tested for NSE.
CD markers
When the CD14 + cells were settled on to bone slices for 2 h and then washed, 88p1.2 % (meanpS.E.M. ; n l 4) showed CD14 + expression, as assessed by direct immunocytochemistry using a confocal laser scanning microscope (Figure 2A ). Other markers were rarely seen (CD3, 1 % ; CD13, 2 % ; CD19, 1 %). After 24 and 84 h of culture with hM-CSF and sRANKL, the percentage of cells showing CD14 decreased rapidly, to 32p4.5 % and 7.6p6.0 % respectively.
Osteoclast generation
Comparison of assays employing unfractionated PBMC, CD14 + cells and CD14 − cells Table 2 . The efficiency of osteoclast generation and the degree of bone resorption obtained with 10& CD14 + cells were similar to those achieved with 10' PBMC, which is likely to reflect the prevalence of CD14 + cells in PBMC. However, when comparing PBMC and CD14 + cell osteoclastogenesis assays, we observed a greater intra-assay variability (P 0.05) in the number of TRAP + MNC per bone slice and in the percentage bone resorption when PBMC were used than when CD14 + cells were used (Table 2) . When CD14 − cells (10&\well) were settled on the bone slices, few were adherent at 84 h (88p26\slice), and fewer (47p7\slice) TRAP + Mo were present after 3 weeks of culture. No TRAP + MNC or bone resorption were evident after 3 weeks of culture (results not shown).
Time course of TRAP + Mo and TRAP + MNC generation and bone resorption in assays employing CD14 + cells
When CD14 + cells were incubated on bone slices in the presence of hM-CSF alone, large numbers of TRAP + Mo were evident by 1 week ( Figure 3A ). The number of TRAP + Mo increased in a linear manner, resulting in an approximate doubling during the 21-day incubation period. Small numbers of TRAP + MNC were present at 14 days, which had increased by 21 days, but no resorption was detected by scanning electron microscopy, indicating that these cells were not osteoclasts.
In the presence of both hM-CSF and sRANKL there was a 30 % increase in Mo from 24 h to 7 days, but throughout the 21 days of the culture there was no overall trend to increase. Substantial numbers of TRAP + MNC were present at 14 days, with a marked increase by 21 days ( Figure 3B) . A small amount of bone resorption was seen at 7 days (when no TRAP + MNC were present) and this increased progressively, with an average of 20-25 % of the bone slice surface resorbed at 21 days ( Figure 3C ). Approx. 5i10$ bone-adherent CD14 + cells generated 165p47 TRAP + MNC (containing " 10$ nuclei) and approx. 5i10$ TRAP + Mo, indicating that about 20 % of the nuclei are eventually contained within osteoclasts. This calculation does not account for cell proliferation and apoptosis that is likely to occur in these cultures.
DISCUSSION
In the present study we have shown that highly enriched CD14 + cells derived from human peripheral blood express mRNA for RANK and differentiate into boneresorbing osteoclasts in the presence of sRANKL and hM-CSF. This was associated with a rapid loss of the CD14 marker over the first few days of culture. Bone resorption was evident by day 7 of culture, preceding the appearance of TRAP + MNC, indicating that a proportion of the CD14 + cells differentiate rapidly to form mononuclear bone-resorbing osteoclasts. In contrast, a significant proportion of the cells remained mononuclear after 21 days. These observations suggest that heterogeneity exists both in the maturity of the CD14 + osteoclast-precursor phenotype and in the potential of the cells to become osteoclasts. However, as we did not extend the cultures beyond 21 days, the possibility exists that these mononuclear cells may differentiate into multinuclear osteoclasts with longer incubation times.
The ability of 10& CD14 + cells and 10' PBMC to produce similar numbers of TRAP + MNC and similar percentage bone resorption is consistent with approx. 14 % of PBMC being CD14 + monocytes. However, the variability of osteoclast generation from PBMC was consistently greater, with some replicates showing virtually no osteoclastogenesis despite the presence of large numbers of TRAP + Mo. Interestingly, we found that unfractionated PBMC expressed OPG mRNA, derived from CD8 − \CD4 − lymphocytes (results not shown). This raises the possibility that increased production of OPG, or other factors, by lymphocytes within some PBMC preparations may result in reduced osteoclast generation. In addition to the strongly CD14 + monocyte, there exists a subset comprising about 10 % of all blood monocytes which is only weakly CD14 + but strongly CD16 + [22] , as well as other minor subsets including CD14 − \CD16 ++ , CD14 + \CD33 ++ and CD14 ++ \CD56 + [23] . The role of these subsets in osteoclastogenesis is unknown.
In vivo, osteoclastogenesis is a complex process involving not only osteoclast haemopoietic precursors and mesenchymal stromal\osteoblasts but also other haemopoietic cells that are not osteoclast precursors but may regulate the process. An example of this was seen in the recent experiments of Horwood and colleagues [24] , who showed that inhibition of osteoclastogenesis by interleukin-18 was an indirect effect, mediated by T lymphocyte granulocyte\macrophage colony-stimulating factor production. Thus, although the availability of recombinant sRANKL has allowed the development of osteoclastogenesis models which do not require co-culture with stromal\osteoblasts, these models employing PBMC essentially remain ' co-cultures ' of osteoclast precursors and accessory haemopoietic cells.
Small numbers of osteoclasts have been generated from haemopoietic precursors, including granulocyte\ macrophage colony-stimulating factor-mobilized PBMC [25] , and CD34 + cells [26] in the absence of stromal\ osteoblasts or the addition of exogenous sRANKL. Faust et al. [27] cultured dense populations of unfractionated PBMC (1.5i10' cells\cm#) for 22 days in the presence of serum alone. A number of calcitonin-receptor-positive mono-and multi-nuclear cells and a minor degree of bone resorption were found, indicating that some genuine osteoclasts were generated. Interestingly, RANKL mRNA was not detectable at day 1, but was present at day 5, declining progressively thereafter to undetectable levels by day 18. In this model, it seems likely that expression of RANKL and M-CSF by subpopulation(s) of cells within the PBMC facilitated the differentiation of small numbers of osteoclasts. Taken together, these studies suggest that, under some circumstances, all the essential elements for osteoclast generation [osteoclast precursors, M-CSF and RANKL, or a factor(s) with a similar effect] can be found in the blood. There is also evidence that non-adherent PBMC (which are predominantly lymphocytes) can generate an inhibitor(s) of osteoclastogenesis that is suppressed by dexamethasone [19] . Therefore, in order to determine ' direct ' versus ' indirect ' effects on osteoclastogenesis, homogeneous populations of osteoclast precursors must be prepared. We believe that the use of highly purified CD14 + cells, as demonstrated here, constitutes the first step in this endeavour. It will now be important to define the phenotype of the subpopulation(s) within the CD14 + population with the highest potential for differentiation into osteoclasts, and also to characterize the effects of other haemopoietic cells on these osteoclast precursors.
